SMi is thrilled to introduce Alzheimer's 2016!
As more and more people live longer and the population ages, Alzheimer's has been identified as one of the biggest health problems in the 21st century. In the UK alone, a new report by the HSCIC has indicated that the number of patients being prescribed with drugs to treat Alzheimer’s has risen six-fold in the last 10 years. A 5 year strategy to fight dementia unveiled by the UK Government last year, reflects greater efforts to tackle the disease in the UK.
Alzheimer’s 2016 will hone in on early intervention strategies as well as solutions to on-going drug development challenges. It will strengthen knowledge in key topics such as; tau aggression; risk profiling; investment options; regulations, MRI imaging and biomarker evaluation, whilst looking at the practicalities of meaningful data from trials and keeping attendees at the forefront of clinical breakthroughs to adapt to the growing need for new treatments.
Understanding behavioural and psychiatric symptoms will be a major focus, as will hearing from a selection of pharmaceutical companies currently modelling disease progression. An exclusive update on funding opportunities and academic drug discovery from Alzheimer’s Research UK, will be just one of the event highlights for 2016.
Key Speakers Include:
As more and more people live longer and the population ages, Alzheimer's has been identified as one of the biggest health problems in the 21st century. In the UK alone, a new report by the HSCIC has indicated that the number of patients being prescribed with drugs to treat Alzheimer’s has risen six-fold in the last 10 years. A 5 year strategy to fight dementia unveiled by the UK Government last year, reflects greater efforts to tackle the disease in the UK.
Alzheimer’s 2016 will hone in on early intervention strategies as well as solutions to on-going drug development challenges. It will strengthen knowledge in key topics such as; tau aggression; risk profiling; investment options; regulations, MRI imaging and biomarker evaluation, whilst looking at the practicalities of meaningful data from trials and keeping attendees at the forefront of clinical breakthroughs to adapt to the growing need for new treatments.
Understanding behavioural and psychiatric symptoms will be a major focus, as will hearing from a selection of pharmaceutical companies currently modelling disease progression. An exclusive update on funding opportunities and academic drug discovery from Alzheimer’s Research UK, will be just one of the event highlights for 2016.
Key Speakers Include:
- Giulio Maria Pasinetti, Saunders Family Chair and Professor of Neurology, Icahn School of Medicine at Mount Sinai
- Luc Ver Donck, Scientific Director, Janssen Research & Development
- Steve Hood, Director, Biotransformation & Drug Disposition, GSK
- Matthew Kennedy, Director, Early Discovery Neuroscience, Merck
- Serge Van der Geyten, Director, Neuroscience External Affairs, Janssen Research & Development
- Michael J O’Neill, Head of Molecular Pathology Group, Eli Lilly
- Claude M Wischik, Executive Chairman, TauRx Therapeutics
- Simon Ridley, Director of Research, Alzheimer’s Research UK
